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Bioavailability of D4 after
Inhalation and Implantation
Exposure to Silicones 
In the November 2001 issue of EHP, Luu
and Hutter (1) described a physiologically
based pharmacokinetic (PBPK) model for
the bioavailability of octamethylcyclotetra-
siloxane (D4) following exposure to D4 by
inhalation and implantation. In this paper
the authors developed a PBPK model that
used a very limited data set obtained after
either single or repeated intravenous (iv)
administration of D4 as a microemulsion
(2). The intravenous pharmacokinetic data
reported by Kirkpatrick (2) were obtained
from a study I helped design and conduct; I
am familiar with the data and with the limi-
tations of the study design for this type of
assessment. Kirkpatrick (2) obtained blood
and tissue samples at various time intervals
after administration of radiolabeled D4 and
determined total radioactivity in these sam-
ples, but did not attempt to distinguish
between parent D4 and D4 metabolites.
Although the data obtained by Kirkpatrick
were for iv dosing, Luu and Hutter (1) actu-
ally used intra-arterial dosing in their PBPK
model. They validated their model by pre-
dicting inhalation kinetics in rats and com-
paring their prediction with a data set pub-
lished by Plotzke et al. (3); they assumed
that the radioactivity measured by Plotzke et
al. (3) was parent D4, with no contribution
from metabolites. Luu and Hutter (1) plan
to use their PBPK model to assess risk after
exposure to D4 resulting from migration
from silicone gel breast implants. In addi-
tion to specific issues about their PBPK
model, I also have several concerns about the
manner in which this model will ultimately
influence any risk assessment performed for
D4. These concerns relate to a) the assump-
tions of the level of D4 in a silicone gel
breast implant, b) the actual level of expo-
sure to D4 arising from a silicone gel breast
implant, c) the limited understanding of the
metabolism of D4 reported by Luu and
Hutter (1), and d) the prediction from their
PBPK model that D4 will bioaccumulate
with repeated exposures. 
The level of low molecular weight silox-
anes (LMWS), both cyclic and linear, that
persist in the polydimethylsiloxane
(PDMS) used to make the silicone gel and
elastomer shell of a breast implant is in the
range of ≤ 0.1%. In a recent comprehen-
sive pharmacokinetic study on PDMS,
Jovanovic (4) measured the actual concen-
tration of D4 to be 0.03% of the PDMS by
weight. Our own analysis of D4 in silicone
gel breast implants shows that D4 levels
rarely exceed 700–1,000 ppm (0.07–0.1%)
(5). This higher level of D4 in the silicone gel
could result during the manufacturing
process. If one conservatively assumes that a
silicone gel breast implant could contain up
to 0.1% D4 and that the average size of a
breast implant is 250 g, then the total D4
content in two breast implants is 500 mg, or
8.7 mg D4/kg body weight based on the U.S.
Environmental Protection Agency’s default
body weight of 57 kg for a woman (6). 
The migration of silicone from a silicone
gel breast implant ranges up to 820 µg/day
(7), with the migration of D4 occurring at a
rate of about 0.58 µg/day (5). For a woman
who weighs 57 kg, this migration equates to a
relatively small exposure of 0.01 µg/kg/day.
Luu and Hutter (1) estimated that the extra
dose of D4 received from a silicone gel breast
implant is 5.7 µg/kg/day, an overestimate by
over 500-fold. The estimate of daily intake
reported by Shipp et al. (8) resulting from
exposure to D4 in a wide variety of personal
care products was 158 µg/kg/day. If we
assume the value reported by Luu and Hutter
(5.7 µg/kg/day) is correct, then the exposure
to D4 resulting from migration from a gel-
filled implant would account for a propor-
tionately small increase in total exposure to
D4 (from 158 µg/kg/day to 164 µg/kg/day).
This small increase has little effect on the ini-
tial risk assessment for D4 (8). 
Two of the references (9,10) cited by
Luu and Hutter (1) to support “migration
of significant amounts of silicone out of gel
implants into surrounding tissue and to the
liver” have been retracted by the authors
(11). Further, Hull (12), a member of the
Magnetic Resonance in Medicine’s Editorial
board, wrote that “as a referee, none of
Garrido’s papers should have been pub-
lished in their current form,” and in a sum-
mary statement concluded that 
the inadequacies, omissions, inconsistencies, and
unresolved questions that are apparent in the
work of Garrido et al. allow only one possible
conclusion: there is no convincing and repro-
ducible evidence of millimolar concentrations of
silicon in tissue or blood. 
The work of Garrido and colleagues (9,10)
certainly does not support the contention
of Luu and Hutter (1) in the introduction
of their paper that 
the migration of significant amounts of LMWS
from silicone gel breast implants … would add
to the dermal or inhalation exposures from per-
sonal care products in a typical woman.
Luu and Hutter (1) postulated that D4
saturates the elimination process, thereby
potentially increasing the delivered dose to
the target tissue and causing accumulation
of D4 in fat, liver, and kidneys. This con-
clusion is based on their analysis of the iv
data (but they actually used intra-arterial
administration). Several studies show that D4
induces cytochrome P450 2B1/2B2 in a
time, dose-dependent, and phenobarbital-
like manner (13,14). Studies conducted by
Plotzke and colleagues (3,15,16) and
Varaprath et al. (17,18) provide evidence
that rats extensively metabolize D4.
Metabolism and subsequent elimination of
hydrophilic metabolites in urine and feces are
important elimination mechanisms for D4 in
mammalian species. In addition, the elimina-
tion of D4 occurs not only by this high meta-
bolic clearance from liver but also by exhala-
tion of parent D4 via the lung. If Luu and
Hutter (1) were correct and D4 did saturate
the enzymes responsible for metabolism, pro-
portionately more D4 would be eliminated
through exhalation. As shown by Plotzke et
al. (3,15,16), in fact, the rates of metabolism
and clearance of D4 and its metabolites sup-
port the conclusions reached with a more
comprehensive PBPK model developed by
Andersen et al. (19); that is, D4 will not be
unusually persistent in mammalian species.
In their discussion, Luu and Hutter (1)
focused much of their attention on the
potential bioaccumulation of D4. The PBPK
model developed by Andersen et al. (19) was
based on an extremely robust inhalation
pharmacokinetic data set for D4 developed
by Plotzke et al. (3) that included exposure to
three concentrations, single and repeated
exposures, and separate measurement of par-
ent D4 and metabolites (15–18). This model
showed that D4 is not expected to accumu-
late with repeated exposures. This lack of
accumulation, despite high fat:blood parti-
tioning, is due to rapid metabolism and the
low blood:air partition coefficient that allows
for ready exhalation of D4. Metabolism does
not saturate until the inhalation exposure
concentration exceeds 500 ppm (v/v). To
assess the validity of the prediction that D4
would not accumulate, we recently collected
blood and fat samples from female rats after
6 months of exposure to D4. As part of a 2-
year bioassay, these female rats were exposed
by inhalation for 6 hr/day, 5 days/week to
700 ppm (v/v) D4. We measured parent D4
concentrations in both the blood and fat and
compared the concentrations at 6 months of
exposure with those obtained at 15 days in
the inhalation pharmacokinetic study by
Plotzke et al. (3). The concentrations in
blood and fat, respectively, at 15 days were
7.2 µg/g and 1,079 µg/g tissue. At 6 months,
the D4 concentrations in blood and fat,
respectively, were 13 µg/g and 1,200 µg/g tis-
sue. These results confirm that D4 does not
accumulate in the body. 
As with any risk assessment, it is essential
to understand both the exposure to target
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ty in experimental animals. The develop-
ment of a PBPK model plays an important
role in calculating the dose delivered to tar-
get tissue from specific exposure conditions.
These PBPK models also can play a role in
understanding the dynamic processes that
occur while the D4 is in the organism.
Recently, D4 was shown to have an effect on
the reproductive system of female rats fol-
lowing inhalation exposure to 500 and 700
ppm (v/v) (20). This effect consisted of a
reduction in mean live litter size and implan-
tation sites. In the F1 generation, there also
was a reduction in mating at 500 and 700
ppm (20). The mode-of-action for these
reproductive effects is the ability of D4 to
block or shift the preovulatory surge of
luteinizing hormone (21). The highest expo-
sure concentration that does not cause a sig-
nificant reproductive effect [i.e., the no-
observed-adverse-effect level (NOAEL)]
appears to be around 300 ppm. The esti-
mate of daily intake reported by Shipp et al.
(8) for D4 exposure from a variety of sources
including personal care products is influ-
enced by two characteristics or assumptions.
First, at the time we completed our initial
exposure assessment, roll-on antiperspirants
(AP) contained up to 60% D4 and account-
ed for about 50% (70 µg/kg/day) of the esti-
mated daily intake. In the last few years,
there has been a shift away from D4 in roll-
on APs such that the estimate of daily intake
today should be about 40–50% lower than
the original value. Second, the primary expo-
sure to D4 in personal care products is der-
mal application. After absorption into the
venous blood, D4 goes to the lung before
reaching other tissues. As D4 passes through
the lung, some is eliminated in the expired
air before entering the arterial circulation.
Based on its partition coefficient, one-half of
the free D4 in the venous blood will be
exhaled during passage through the lung.
This first pass effect, predicted by the PBPK
model developed by Andersen et al. (19) is
consistent with the physical properties of D4
and therefore further lowers the estimated
daily intake. Luu and Hutton (1) estimated
a daily intake or exposure resulting from
migration of D4 from a silicone gel breast
implant to be 5.7 µg/kg/day, which is likely
to significantly overestimate the actual daily
intake. However, if we conservatively esti-
mate the daily intake from personal care
products to be 78 µg/kg/day (based on the
reduced use of D4 in roll-on APs as dis-
cussed above) and add the estimated daily
intake or exposure by Luu and Hutter, then
the estimated total daily intake for D4
becomes 85 µg/kg/day. Exposure of rats to
300 ppm (v/v) of D4 for 6 hr/day equates to
an inhaled dose of 45,000 µg/kg/day using
an absorption value of 5%, as determined in
our inhalation pharmacokinetic studies (3).
These values give a margin of safety (or
exposure), as determined by dividing the
NOAEL by the estimated daily intake, of
over 500. A margin of exposure (MOE) of a
specified magnitude indicates that exposure
at or below the corresponding estimated
intake level is not expected to result in
adverse effects in the exposed populations.
An MOE of 100 is typically considered
large enough to be health protective when
the NOAEL is based on animal data. The
components of the MOE can be thought of
as the typical factors of 10 for interspecies
extrapolation (from animals to humans) and
a factor of 10 for intrahuman variability,
resulting in an MOE of 100. 
In summary, Luu and Hutter (1)
reported that they have developed a PBPK
model for exposure to D4 via two routes:
a) inhalation in association with daily use
of multiple personal care products, and b)
migration of small amounts of silicone fluid
from silicone gel breast implants. Their
PBPK model is built from data generated
by intravenous administration of D4 as a
microemulsion (2) and then modeled for
intra-arterial dosing. They assumed that all
radioactivity was parent D4, even though
there is significant conversion of D4 to
hydrophilic metabolites. A more complete
PBPK model (3) was developed from an
extensive inhalation data set on D4, includ-
ing evaluation of metabolism of D4. This
more comprehensive model and the actual
data from our 6-month inhalation study
show that there are only modest increases
of D4 concentration in fat on repeated
exposures to D4 compared to concentra-
tions achieved after single exposures. Luu
and Hutter (1) also overestimated the con-
tributions to the daily intake resulting from
the migration of D4 from a breast implant.
However, this overestimation of the daily
intake by Luu and Hutter does not signifi-
cantly change the MOE for D4. The con-
servative MOE of > 500 indicates that cur-
rent use practices with D4 have adequate
safety margins 
Robert G. Meeks
Dow Corning 
Midland, Michigan
E-mail: robert.meeks@dowcorning.com
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Bioavailability of D4
We would like to comment on a paper by
Luu and Hutter (1) published in the
November 2001 issue of EHP. We have
developed multidose route, multi-species
PBPK models for D4 over the past several
years. Our PBPK models have been present-
ed in abstract form at several national meet-
ings, and the complete inhalation model for
D4 in the rat was published earlier this year
(2). In their paper, Luu and Hutter (1)
incorrectly attribute several conclusions to
our earlier abstracts, including the comment
that our model did not describe blood con-
centrations during and after exposure.
Surprisingly, they did not cite conclusions
from our complete, peer-reviewed docu-
mentation of our model. We would like to
point out some important differences
between their model and our D4 model. We
would like to address several issues: a) the
unconventional model structure and inap-
propriate use of available pharmacokinetic
data to estimate the blood:air partition coef-
ficient by Luu and Hutter (1); b) the
process by which all available pharmacoki-
netic data should have been used to ensure
adequate validation of their PBPK model;
and c) the unusual kinetic behavior of D4
compared to other volatile organic com-
pounds that needs to be captured in any
kinetic model for this compound.
A major difference in Luu and Hutter’s
model (1) and our published model (2) is
the value used for the blood:air partition
coefficient (Pb:a). Our estimate of Pb:a
derived from the measured concentrations
of parent D4 in blood at the end of a 6-hr
exposure was 0.8; our direct measurements
of the Pb:a by equilibration of D4 between
blood and air in vitro gave a value near 4.0.
Luu and Hutter used a much higher value
of 20 and reported that they were able to
describe both the rat and human inhalation
results. It is of interest to determine why
there would be such a large discrepancy in a
critical parameter between the two models. 
Luu and Hutter’s model for D4 in the
rat (1) is based on studies in which total
radioactivity was measured in blood after
exposure of rats to 14C-D4. Luu and Hutter
(1) used the radioactivity data from Plotzke
et al. (3) and assumed that the radioactivity
in blood was parent compound. In our
work, we modeled parent D4 and metabo-
lites separately. By the end of the 6-hr
inhalation exposure in rats, the majority of
radioactivity in blood is metabolite (about a
3- to 4-fold greater concentration of
metabolite vs. parent D4 at the end of the
exposure). After the 6-hr exposure, D4 is
rapidly eliminated by exhalation compared
to the metabolites, and the discrepancy
between total radioactivity and parent D4
only increases. To predict these artificially
high blood levels and retain these high con-
centrations for long periods of time, Luu
and Hutter’s model requires an artificially
high estimate of the partition coefficient,
thus the use of 20 in their model versus 1.0
in our model in which parent D4 and
metabolites were described separately. 
Luu and Hutter (1) then scaled the
model with the high partition coefficient to
humans. In this case the data in their paper
was for parent D4; nonetheless, they still
showed good correspondence between data
and model predictions. We believe that this
agreement is quite misleading and related
to differences between their human model-
ing approach and conventional approaches
used with other volatiles. Their ability to fit
the human D4 was based on an artificial
constraint added to limit retention of
inhaled D4.
Based on the equations of Ramsey and
Andersen (4), a paper cited as the basis of
Luu and Hutter’s work, the concentration
of styrene in the arterial air (Cart) could be
approximated from a steady-state formula
published by Andersen (5):
[1]
where Qalv is the alveolar ventilation, EH is
hepatic extraction, QH is the hepatic blood
flow, and Cinh is the inhaled concentration
of compound. In PBPK models, inputs
include partition coefficients, inhaled con-
centrations, and the suite of physiologic fac-
tors, including blood flows, breathing rates,
and characteristics of metabolizing tissues.
Using all of these factors together, it is possi-
ble to predict the amount of inhaled com-
pound that is retained during respiration.
For modeling exposures in rats, Luu and
Hutter (1) correctly used the ventilation ×
the inhaled concentration as the input term
to the arterial blood in the rats. In contrast,
for the human modeling Luu and Hutter (1)
cited the differences (input – output) mea-
sured in a human study from the University
of Rochester (6) and applied them as a con-
straint on the model. Thus, their input is
(Qalv × Cinh × proportion retained). Because
the proportion retained was only 0.1, the
model required an anomalously high
blood:air partition coefficient to achieve
blood concentrations equal to the inhaled air
concentrations. (This behavior follows from
Equation 1 if the proportion retained is
included empirically.) Our PBPK model for
D4, following previous approaches with
volatile compounds such as styrene,
describes parent D4 concentrations in rat
and humans without artificial constraints on
uptake. The proportion retained is an out-
put of the model, not a constraint. In this
fashion, both rat and human uptake curves
are adequately described in our modeling
efforts with Pb:a = 1.0. 
The novel kinetic behavior referenced in
the title of our paper (2) is the persistence of
nonexchangeable D4 in blood at long times
after exposure. We only identified the
necessity to include this bound form in
blood because of our efforts to fit blood and
exhaled D4 during both the exposure and
the postexposure periods. Luu and Hutter’s
model (1) also included blood sequestration
from the plasma pool of D4. (The equation
in their paper for the weakly bound com-
partment appears to be incorrect. The last
term in their paper for this equation should
be ksi × Cwk rather than ksi × Cstr. According
to the author’s description
where Cai is the concentration of D4 dis-
solved in plasma; Cwk is the concentration
of D4 weakly protein bound in plasma; Cstr
is the concentration of D4 strongly protein
bound in plasma; kwi is forward rate con-
stant for weak protein binding of D4 in
plasma; ksi is forward rate constant for
strong protein binding of D4 in plasma; kso
is reverse rate constant for strong protein
binding of D4 in plasma; kwo is reverse rate
constant for weak protein binding of D4 in
plasma; Vweak is the volume of weakly
bound plasma.
Another similarity in structure of
the two models is the use of multiple fat
compartments. Luu and Hutter (1) used a
diffusional movement from a single fat
compartment into a sequestered compart-
ment within the main fat compartment. In
our model, we described different fat com-
partments within the body with different
time constants for equilibration. Luu and
Hutter (1) referred to blood flow to deep
fat, although the description and equations
indicate a diffusional movement from weak-
ly bound fat to the deep fat compartment.
Their equation for the deep fat compart-
ment is also inaccurate as written; it should
show a term for movement from the weakly
bound fat compartment. In its present form
in their paper (1), the rate of change of mass
for the deep fat would always be zero. [The
equation for the lung compartment in Luu
and Hutter’s paper (1) also has an error,
with Clung appearing twice in the second
term of the mass balance equation.] 
The model structure used by Luu and
Hutter (1) for intravenous dosing actually
is for intra-arterial dosing, in which the
compound is placed in the arterial blood and
V
dC
dt
kC kC – kC – k C weak
wk
wi ai so str wo wk si str =+ ,
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,
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into the venous blood, where it must tra-
verse the lung with opportunity for exhala-
tion before passing to the arterial blood. For
a compound with a low Pb:a such as D4, it is
important to have physiologic realism in the
dosing route in order to estimate exhaled D4
accurately after intravenous dosing. 
Another issue is that Luu and Hutter
(1) should have used all available pharma-
cokinetic data to insure adequate validation
of their PBPK model. After configuring the
model for intravenous dosing, a practice
common to many pharmacokinetic studies,
Luu and Hutter (1) predicted plasma and
fat concentrations for a single inhalation
exposure of rats to D4. The model overesti-
mated the early time points in fat. In addi-
tion, the overall time course in plasma was
underestimated for this one attempt at
extrapolation and validation. Surprisingly,
this validation exercise used a single study
from an extremely rich data set on the
inhalation pharmacokinetics of D4 in rats.
The data used for dose route extrapolation
and validation once again were for radioac-
tivity rather than for parent D4 in blood
and fat, whereas their pharmacokinetic
model was purportedly for parent D4 alone. 
Plotzke et al. (3) performed pharmaco-
kinetic studies of inhaled D4 in male and
female rats at three exposure concentra-
tions for both single and multiple expo-
sures. These inhalation studies generated
important data on tissue time courses of
D4 in a large set of tissues, as well as in
exhaled breath concentrations. Similarly,
the available human data for interspecies
extrapolation include exhaled breath con-
centrations and blood concentrations from
volunteers (6). Any model validation exer-
cise should consider all available kinetic
information and not rely on a limited
selection of these results. Luu and Hutter’s
(1) conclusions regarding validation should
be regarded as preliminary until their
PBPK model is rigorously tested against
more complete data sets. For Luu and
Hutter to assert that prediction of a limited
set of available human data from an
unconventional model for inhalation
constitutes dose–route and interspecies val-
idation of their PBPK model is an over-
interpretation of available information. 
A third area of concern in Luu and
Hutter’s study (1) involves the unusual
kinetic characteristics of D4. There is little
doubt that the defining characteristic of D4
is its lipophilicity, including a high
fat:blood partition coefficient (Pf). We
determined by vial equilibration methods
that Pf was 500–600 in rats (2). The overall
kinetic behavior of D4, however, is related
to several important characteristics:
lipophilicity, high metabolic clearance from
liver, and high exhalation clearance due to
its relatively low Pb:a. This suite of charac-
teristics insures that D4 does not bioaccu-
mulate excessively with repeated dosing.
Although both Luu and Hutter’s model
(1) and our PBPK model agree that the
fat–time constant is of the order of several
weeks, D4 behaves much differently from
poorly metabolized, nonvolatile com-
pounds that bioaccumulate extensively with
multiple exposures. The blood levels of D4
do not increase with daily exposures and
the fat concentration increases only slightly,
as noted in the multiple exposure studies
reported by Dow Corning scientists and
analyzed with our more complete PBPK
model (2). On a fairly minor note, the
pharmacokinetic models developed by both
groups are linear, low-dose models. Luu
and Hutter (1) called the kinetics of the
intravenous administration nonlinear. The
appropriate terminology would be polyex-
ponential, not nonlinear.
We are pleased to see PBPK modeling
approaches for evaluating interspecies dif-
ferences in disposition appear in EHP;
however, Luu and Hutter’s statements
regarding our inability to model postexpo-
sure D4 levels are inaccurate. The post-
exposure kinetic behavior of D4 is deter-
mined by a combination of free D4 and D4
in a nonexchangeable compartment. These
time-course curves have been accurately
described at various concentrations after
both single and multiple exposures in male
and female rats with our PBPK model
structure (2). As Luu and Hutter noted, we
did not report extrapolation to humans.
The reason for this was that we were in the
process of completing a more definitive
examination of human inhalation kinetics
from two complete human data sets on a
total of 18 exposures. These analyses have
now been completed (7,8). 
To summarize our human modeling,
we found that the structure of the rat
PBPK model for D4 with a Pb:a of near
1.0, when scaled appropriately, was entire-
ly adequate for describing all available data
from human volunteers. We are concerned
about the inaccurate attribution of conclu-
sions of our modeling efforts by Luu and
Hutter (1) and appreciate the opportunity
to provide clarification on these points. We
emphasize that the kinetics of D4 are well
described with Pb:a = 1.0 in both rats and
humans, when sequestration in blood
lipids is included in the model structure.
Because of the high rate of metabolism and
exhalation of poorly soluble D4 from
blood, there should be little tendency for
D4 to bioaccumulate in any tissues upon
repeated exposures. 
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Rebuttal and Critical Review
of Andersen et al.’s D4 PBPK
Model
The letters of Meeks and Andersen et al.
regarding our paper in EHP (1) included
inaccurate statements and misconceptions
about our pharmacokinetic model of D4. 
After reviewing Andersen et al.’s recent
paper (2), we found several shortcomings.
First, Anderson et al. (2) used an unconven-
tional experimental method to underesti-
mate the affinity of D4 for blood and fat;
these partition coefficients were not compa-
rable to those obtained for other lipid solu-
ble organic chemicals. They further reduced
Environmental Health Perspectives • VOLUME 110 | NUMBER 8 | August 2002 A 445
Correspondencethese experimental measurements in order
to “fit” a 10-compartment model, which
included 3 deep compartments in the lungs,
fat, and liver. Andersen et al. used these low
values to underestimate potential D4 accu-
mulation in fat and increase its clearance. 
Second, Andersen et al. (2) did not vali-
date and verify their PBPK model using
independent data from intravenously (iv)
treated rats. When we used Andersen et al.’s
parameters for D4 [blood:air partition coef-
ficient (Pb:a), fat:blood partition coefficient
(Pfat), and metabolism rate (Vmax)] in our
own model, our results did not fit the iv
experimental rat data, especially regarding
D4 tissue distribution in fatty tissues.
Andersen et al.’s conclusions about the dis-
position and fate of D4 also were not
substantiated by the experimental rat inhala-
tion data because high lipid solubility and
slow desorption would favor accumulation
in fatty tissues, as in the case with styrene.
Third, in their letter, Andersen et al.’s
criticism about the dose rate of D4 from a
breast implant was incorrect; the dose rate
reported was for D4 leaching from the
saline-filled breast implants and not from
the silicone gel-filled breast implants. 
We question the validity of Andersen et
al.’s model (2) and believe that their predic-
tions about the safety assessment of D4, a
component in silicone personal products
and breast implants, may be misleading. 
Andersen et al. (2) used a low Pb:a (0.88)
in their model, despite reporting a measured
experimental value of 4.3. They also used an
unconventional method to measure the Pb:a
and blood:tissue partition coefficient (Pb:t). 
To measure the Pb:a and Pb:t of D4,
Andersen et al. (2) placed liquid D4 and
matrices such as blood, fat, lung, and liver in
separate glass scintillation vials. All of the
vials were subsequently placed in an enclosed
500-mL beaker. The D4 was not in physical
contact with the blood or any other matrices
throughout the experiment. Using this
method, a low volatility compound like
D4 would have to vaporize, diffuse through
a gas space, and diffuse into a stagnant blood
or tissue phase with liquid mass transfer
resistance. This process would take time to
reach equilibrium, but did Andersen et al.
allow enough time for equilibrium to
occur? Shields et al. (3), who measured D4
concentrations in indoor air using a state-
of-the-art analytic method, indicated that
the sampling intervals for D4 should be in
weeks, not hours, in order to reach equilib-
rium. Andersen et al. (2) reported that they
agitated for 24 or 48 hr and measured Pb:a
at two unknown time points. In fact, if the
samples were allowed to reach equilibrium,
their measurement of the Pb:a of D4 (4.3)
might reach our estimated value of 20. The
measured concentrations of D4 in blood
based on molecular diffusion between the
vapor phase of D4 and blood are not reliable
unless they used long sampling intervals (3).
Because Andersen et al. (2) did not describe
internal standards for the experiment, it is
likely that the percentage recovery was low
after 24–48 hr. The same method was also
used to underestimate other partition coeffi-
cients for fat, lungs, and kidneys.
A more accurate and direct measurement
of Pb:a (or Ptissues) would be to place several
milliliters of the viscous D4 liquid in direct
contact with the tested matrix (e.g., whole
blood, fat, liver, etc.) in a closed scintillation
vial (4). The headspace (air) concentration
and matrix concentration of D4 should then
be quantified during several time intervals
following agitation. This minimizes the
equilibrium problems not addressed by
Andersen et al. (2).
The physical properties of D4 (Table 1)
play an important role in its tissue distribu-
tion and excretion; thus it is important that
the use of arbitrary “fitted” parameters be
avoided. This arbitrary low value of Pb:a used
by Andersen et al. (2) differed by a factor of
5 from the in vitro evaluation. Similarly, the
partition coefficients used for fat and other
tissues also varied widely from their experi-
mental data (2). For example, Andersen et
al. used a Pfat of 550.6 for instead of their
experimentally determined value of 2,089 so
their model would fit the data.
The low Pb:a value is not comparable to
those of other organic chemicals with prop-
erties similar to those of D4. As shown in
Table 1, the higher the volatility, the smaller
the value of Pb:a of an organic compound.
For example, because benzene is more
volatile than styrene, it has a smaller Pb:a
(75% smaller) than styrene (Table 1).
According to Andersen et al.’s results (2),
D4 would be more volatile than benzene in
blood. This is inconsistent with the
observed volatility because benzene has a
boiling point of 80.1°C, whereas D4 has a
boiling point of 175°C (Table 1). Because
D4 has a lower volatility than both styrene
and benzene, its Pb:a would be expected to
be at least as large as the values reported for
these two chemicals, and not smaller
(Table 2). The D4 Pb:a would not be expect-
ed to have a value as low as 0.88, which is
outside the range of all of the chemicals list-
ed in Table 2. Ramsey and Andersen (16)
reported a Pb:a for styrene of 40.2 (Table 1). 
Under the scenario of Andersen et al.
(2), if both 1 µg D4 and 1 µg of a much
more volatile component such as benzene or
another chemicals in Table 2 were added to
blood, the D4 would vaporize more readily.
This is due to its partition coefficient, which
favors transfer to the gas phase. Thus, D4,
which boils at 175°C, would be more
volatile than benzene, which boils at
80.1°C, a situation which makes no sense.
As we discussed in our paper (1), the
physical properties of D4 favored its
absorption into fat. High absorption of D4
(100%) by the iv route and slow desorp-
tion, as well as a long half-life in fat (t1/2 =
18 days), were attributable to the high Pb:a,
Pfat, and high lipid solubility of D4 [log
octanol/water partition coefficient (Kow)  =
5.1]. For similar reasons, other highly lipid
soluble organic compounds such as styrene,
with high Pb:a and Pfat, tend to accumulate
in the fat tissue of rats and humans (5–7). 
To compensate for this estimate of a
thermodynamic property in blood and to
“fit” the rat data for inhalation exposure,
Andersen et al. (2) modified their basic
model with 6 compartments to a refined
model with 10 compartments, including
deep compartments (deep lung, deep liver,
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Table 1. Comparison of physical properties of D4, styrene, and benzene.
Property D4 Styrene Benzene
Melting point (°C) 17.5 –30.6 5.5
Boiling point (°C) 175.4 145–146 80.1
Vapor pressure (mmHg) 1 (25°C) 4.5 (20°C) 2.3 (3°C)
Pb:a 0.88a 40–52 17.8
Solubility in water 56 ppb 300 ppm —
Log Kow 5.1 2.95 2.14
aWe used a value of 20 for Pb:a.
Table 2. Blood:air (Pb:a) and blood:fat partition coefficients (Pfat) of some known VOCs.
Compound Log Kow Pfat Pb:a
Hexane 3.87 69.43 2.29
Isoprene 2.42 38.5 1.87
1,1,1-Trichloroethane 2.48 45.66 5.76 
Tetrachloroethene 3.40 86.67 18.9
Benzene 2.14 28.03 17.8
Toluene 2.64 56.72 18
p-Xylene 3.15 42.32 41.3
Styrene 2.95 86.47 40.2
Chlorobenzene 2.86 21.5 59.4deep fat). But any scenario can be fitted by
simply adding more compartments.
However, adding more mass balance equa-
tions requires more biochemical parameters,
which may not be available or accurately
measured. 
In our study, we derived the Pb:a as the
reciprocal of the D4 Henry’s Law Constant,
which is its published water:air partition
coefficient (a value ranging from 3 to 32)
(8–11). The value we used in our model
was within the range reported by these inde-
pendent investigators (8–11). Still, we
included in our paper (1) a discussion of the
discrepancy caused by blood to the aqueous
Henry’s Law Constant of D4, and we also
cited the paper that supported these obser-
vations (4). We believe that Andersen et al.
(2) did not take into account the Pb:a of
lipophilic organic compounds described by
Beliveau and Krishnan (4). 
Even though our Pb:a is significantly
larger than that reported by Andersen et al.
(2) we predicted that the absorbed D4
would be mostly exhaled [range, 42–59%
in humans; see Table 6 of our paper (1)].
We do not understand Andersen et al.’s
comment in their letter that we did not pre-
dict significant exhaled D4. Recalculating
the exhaled air amount using the following
material balance on the exhaled air may
clarify our concerns to Andersen et al. 
[1]
In preparing this response, we ran our
PBPK model again using Andersen et al.’s
fitted values (2) for Pb;a, Pfat, and Vmax for
metabolism rate (8 times higher than our
Vmax value). The results in Figure 1 show
that the model using parameters employed
by Andersen et al. (2) predicted poorly the
D4 levels in fat while predicting reasonable
plasma D4 levels following a single, low-
dose iv injection. Using Andersen et al.’s
parameters (2), we found that > 80% of D4
is exhaled after iv exposure. Therefore, this
would cause underprediction of D4 accu-
mulation in fat, experimentally found to be
16% of the iv dose. As shown in Figure 5 in
our paper (1), our model gave excellent sim-
ulations of the rat iv (12) and rat inhalation
data (13). 
Two structurally different PBPK mod-
els could not both be correct, and both
models fit the rat inhalation reasonably
well. This leads us to believe that there are
other shortcomings in Andersen et al.’s
study (2): 
• Andersen et al. (2) based their model on a
rat inhalation study in which the absorp-
tion and elimination rates are compro-
mised. Only 10% of the exposed D4 in the
air is absorbed, compared to 100% absorp-
tion of D4 with iv exposure. The dose
absorption is limited from the mass trans-
fer resistance in the lungs. Using a low
Pb:a, Andersen et al. reported that > 50%
of the D4 absorbed is eliminated in the
expired air, whereas they assumed the
metabolism rate of D4 to be 8 times higher
in their model than in ours. The unusual
kinetics could not be confirmed by other
published studies. 
• Andersen et al.’s model lacks validation
and verification using independent data
such as included in the rat iv study (12), so
their conclusions about the disposition of
D4 are best described as preliminary. 
• Andersen et al.’s model is not accurate
because they failed to measure partition
coefficients for both parent compounds
and metabolites for the 10 compartments
including 3 deep compartments (lungs,
liver, and fat). Instead, they have to curve
fit, leading to errors and uncertainty
regarding D4 distribution in fatty tissues
especially. 
• Andersen et al.’s conclusions on D4 kinetics
even contradicted what others (13,14)
reported regarding D4 kinetics. In fact, they
reported that D4 plasma and tissue distribu-
tions resemble other volatile organic com-
pounds such as styrene, which were found
to accumulate in fat tissues of both experi-
mental animals and exposed workers (5–7). 
• Andersen et al. (2) failed to determine
accurate D4 pharmacokinetic data which
show that D4 is retained in fat. Because
8–10% of D4 dose was found in fat 7
days postexposure and because rats were
to be exposed daily for 14 days, it is hard
to believe that D4 would not retain and
accumulate in the body. 
In our paper (1), we estimated the maxi-
mum dose rate of residual D4 that could
migrate from the silicone envelope of a breast
implant to be 5.7 µg/kg/day based on Fick’s
Law of Diffusion. We estimated a leaching
rate of 95% in 30 days for the thin shell of a
saline-filled breast implant surrounded by
fatty tissues. The diffusivity of 5.4 × 10–8
cm2/sec was consistent with published values
for other chemicals (15). Our reported dose
rate was the dose rate of D4 leaching from
saline-filled breast implants. The dose rate of
D4 leaching out of implanted silicone gel-
filled breast implants could be easily deter-
mined, if needed. 
In their letter, Andersen et al. correctly
identified a typographical error in the
Appendix regarding the material balance on
the lung. The correct equation is as follows:
In this equation, Cai is a venous blood con-
centration as defined by the equation at
the mix point [Appendix of our paper (1)].
It is not an arterial concentration, as sug-
gested by Andersen et al. In this nomencla-
ture, a = average. Thus, unlike the claims
of Andersen et al. in their letter, this model
does not artificially limit the exhalation of
D4. Any introduced D4 will flow through
the lung in a physiologically realistic man-
ner, despite claims to the contrary. The
above equation is equivalent to the tubular
equilibrium lung used in the styrene model
(16). The capture efficiency we used in both
the rat and human models was similar and
was only used to determine the delivered
dose to the rat or human body as described
in the Appendix of our paper (1). In the ref-
erence (14) cited in our paper, the delivered
dose was experimentally determined by
measuring the gas flow and inlet and outlet
concentrations of D4 at the rebreathing tube
connections. We used the same model
structure for both the rat and the human.
Andersen et al. agreed that our rat inhala-
tion model was correct because the human
model had an identical structure. 
In their letter, Andersen et al. also
claimed that the “accumulation in the
strongly bound fat compartment would
always be zero.” Figure 2 shows the accu-
mulation in this compartment for F344
rats after low-dose inhalation (13).
It is informative to use animal data in
a PBPK model to predict D4 dose metrics
in an animal body. This approach also
allows the determination of the internal
dose in target tissues, which can then be
extrapolated to humans and correlated
with the toxicity. However, models should
be physiologically realistic and should not
be used to predict phenomena beyond the
reasonable bounds of the data by “fitting”
highly restrictive cases. In an accurate
model, the following problems should be
avoided: 
V
dC
dt
QC –QC H –Q C t lung
lung
ta i lung air air lung =
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Figure 1. Comparison of predicted and
experimental D4 concentrations in fat and plasma.
The experimental concentration in fat is from our
model (1), and other values are from Andersen et
al. (2). Andersen et al.’s model underpredicts the
accumulation of D4 in fat.
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Predicted concentration in plasma• Artificially high pulmonary clearance of D4
resulting from use of a Pb:a that is not com-
parable to one obtained experimentally.
• Use of unconventional methods to reduce the
potential of accumulation in target organs.
• Overestimation of the rate of metabolism,
which is caused by a reduced absorbed
dose resulting from inhalation exposure. 
• Inappropriate use of the inhalation model
for D4 to examine the disposition and fate
of D4 leached from silicone breast implants.
Because of these problems with
Andersen et al.’s model (2), the authors
underestimated the potential bioavailability
of D4 and were unable to predict its bioac-
cumulation after repeated exposures or
long-term exposure that occurs when D4
leaches from silicone breast implants.
Hoan-My Do Luu
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Figure 2. Accumulation of D4 in strongly bound fat
of F344 rats after low-dose inhalation.
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